Safety and Tolerability Study of Oral OPC-34712 as Maintenance Treatment in Adults With Schizophrenia
Status: | Completed |
---|---|
Conditions: | Schizophrenia |
Therapuetic Areas: | Psychiatry / Psychology |
Healthy: | No |
Age Range: | 18 - 65 |
Updated: | 10/2/2013 |
Start Date: | September 2011 |
End Date: | March 2016 |
Contact: | Compass Schizophrenia |
Email: | compass.schizophrenia@quintiles.com |
A Long-term, Phase 3, Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Oral OPC-34712 as Maintenance Treatment in Adults With Schizophrenia
The purpose of this study is to assess the long-term safety, tolerability and efficacy of
oral OPC-34712 as monotherapy in adults with schizophrenia.
Schizophrenia is a severely debilitating mental illness that affects approximately 1% of the
world population. Hallucinations and delusions are the most striking characteristic positive
symptoms of schizophrenia; however, more subtle negative symptoms (eg, social withdrawal and
lack of emotion, energy, and motivation) may also be present. The first antipsychotics
developed for the treatment of schizophrenia were effective against positive symptoms, but
showed little efficacy for negative symptoms and were also associated with a high incidence
of side effects. Second generation antipsychotics, represent a significant advancement in
the treatment of psychotic disorders because they are effective and at the same time exhibit
fewer side effects than first generation antipsychotics. Although generally safer than
first generation antipsychotics, the second-generation antipsychotics are not devoid of
undesirable side effects such as Hyperprolactinemia and weight gain. In addition, the
safety of these drugs vary considerably.
Inclusion Criteria:
1. Male or female subjects between 18 and 65 years of age, with a diagnosis of
schizophrenia, as defined by DSM-IV-TR criteria
2. Outpatient status at last visit of Trial 331-10-230 or Trial 331-10-231
3. Willing to discontinue all prohibitive psychotropic medications to meet protocol
required washouts prior to and during the trial period.
4. Other protocol specific inclusion criteria may apply.
Exclusion Criteria:
1. Females who are breast-feeding and/or who have a positive pregnancy test result prior
to receiving study drug
2. Subjects with a current DSM-IV-TR Axis I diagnosis of:
- Schizoaffective disorder
- MDD
- Bipolar disorder
- Delirium, dementia, amnestic or other cognitive disorder
- Borderline, paranoid, histrionic, schizotypal, schizoid or antisocial
personality disorder
3. Subjects presenting with a first episode of schizophrenia
4. Other protocol specific exclusion criteria may apply.
We found this trial at
17
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials